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Abstract 
Background & Aims: Colorectal cancer (CRC) is highly metastatic. Metastases spread directly into 
local tissue or invade distant organs via blood and lymphatic vessels, but the role of lymphangiogenesis 
in CRC progression has not been determined. Lymphangiogenesis is induced via vascular endothelial 
growth factor C (VEGFC) activation of its receptor, VEGFR3; high levels of VEGFC have been 
measured in colorectal tumors undergoing lymphangiogenesis, and correlated with metastasis. We 
investigated VEGFC signaling and lymphatic barriers in human tumor tissues and mice with orthotopic 
colorectal tumors.  
 
Methods: We performed immunohistochemical, immunoblot, and real-time PCR analyses of colorectal 
tumor specimens collected from patients; healthy intestinal tissues collected during surgeries of patients 
without CRC were used as controls. CT26 CRC cells were injected into the distal posterior rectum of 
BALB/c-nude mice. Mice were given injections of an antibody against VEGFR3 or an adenovirus 
encoding human VEGFC before orthotopic tumors and metastases formed. Lymph node, lung, and 
liver tissues were collected and evaluated by flow cytometry. We measured expression of vascular 
endothelial cadherin (CDH5) on lymphatic vessels in mice and in human intestinal lymphatic 
endothelial cells. 
 
Results: Levels of podoplanin (a marker of lymphatic vessels), VEGFC, and VEGFR3 were increased 
in colorectal tumor tissues, compared with controls. Mice that expressed VEGFC from the adenoviral 
vector had increased lymphatic vessel density and more metastases in lymph nodes, lungs, and livers, 
compared with control mice. Anti-VEGR3 antibody reduced numbers of lymphatic vessels in colons 
and prevented metastasis. Expression of VEGFC compromised the lymphatic endothelial barrier in 
mice and endothelial cells, reducing expression of CDH5, increasing permeability, and increasing 
trans-endothelial migration by CRC cells. Opposite effects were observed in mice and cells when 
VEGFR3 was blocked. 
 
Conclusions: VEGFC signaling via VEGFR3 promotes lymphangiogenesis and metastasis by 
orthotopic colorectal tumors in mice and reduces lymphatic endothelial barrier integrity. Levels of 
VEGFC and markers of lymphatic vessels are increased in CRC tissues from patients, compared with 
healthy intestine. Strategies to block VEGFR3 might be developed to prevent CRC metastasis in 
patients. 
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Introduction 
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in the Western 
world1. Although it can spread in a variety of ways, lymphatic vessel (LV) invasion and metastasis are 
common in CRC early stages2. Previous studies have shown that vascular endothelial growth factor 
(VEGF) family members and their receptors (VEGFR) contribute to lymphangiogenesis and the 
metastatic process in CRC2. In fact, high levels of VEGFC and its receptor have been described to 
promote tumor-associated LV expansion, thus becoming one of the most efficient pathways in 
regulating lymphangiogenesis, during CRC dissemination3-5. However, functional studies regarding 
lymphangiogenesis and lymphatic metastasis are still lacking in CRC. The lymphatic system plays 
critical roles in the maintenance of fluid homeostasis, immune response, and cancer progression6, and 
to exert its biological functions it undergoes lymphangiogenesis, a process of growth and expansion of 
the lymphatic vessels. Lymphangiogenesis is activated by the binding of VEGFC and VEGFD to their 
receptor VEGFR37, even if no association of VEGFD expression has been found with CRC lymphatic 
spread8. Even though VEGFC interacts with VEGFR2, which is primarily involved in the induction of 
angiogenesis9, one of the major physiological functions of this growth factor is generally accepted to be 
the inducer of LV growth10. 
Tumor metastasis is responsible for most cancer related deaths. The metastatic process can be 
described in several steps which involve the transmigration of cancer cells from the primary tumor into 
the microvascular or the lymphatic endothelium (intravasation and/or extravasation), and subsequently, 
the formation of a secondary tumor at a distant targeted organ11. The experimental manipulation of 
VEGFC together with the blocking of VEGFR3 activation has been studied in several cancer animal 
models, providing functional evidences that VEGFC is able to induce tumor lymphangiogenesis, and 
concomitantly promote metastasis formation in various distant organs12-14. One of the main restrictions 
of tumor cell intravasation through the lymphatic system is LV integrity15, which is strictly related to 
the organization of interendothelial adherens junction proteins. These junctions are formed by the 
homotypic interaction of vascular endothelial cadherin (VE-Cad)16. Upon cell-cell adhesion, cadherin 
units form a core adhesion complex on adjacent cells via their extracellular domains16. In greater detail, 
the VE-Cad intracellular region forms a complex with an intracellular protein network, including α-, β- 
and γ-catenin and p12017, thus contributing to the strength of intracellular adhesion18. Phosphorylation 
of VE-Cad on Tyr residues disrupts endothelial cell adherens junctions by causing the dissociation of 
catenins from VE-Cad, facilitating the diapedesis of leukocytes and metastatic cancer cells19. It has 
been reported that an aberrant localization of VE-Cad on blood vessels is responsible for cancer cell 
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intravasation and extravasation, thus increasing the metastatic spread of several tumors, including 
CRC19. VE-Cad expression on the microvascular endothelial cell membrane depends on its 
internalization and degradation, and one of the mechanisms mediating these two events is the activation 
of VEGFR2 by its ligand VEGFA12. No mechanistic data is however available regarding the role of 
VEGFR3 signaling on lymphatic endothelial cell adherens junctions during CRC spreading. In the 
present study, with the use of an orthotopic xenotransplantation mouse model of CRC, we demonstrate 
that VEGFC binding to VEGFR3 controls the metastatic spread through the maintenance of lymphatic 
endothelial barrier integrity. 
 
Material and Methods (See also Supplemental Material and Methods) 
Patients 
Tumoral colon tissues were obtained from surgical specimens of CRC patients at different TNM stages, 
ranging from pT1N0 to pT4N2bM1b. Healthy tissues from the intestine of patients admitted for bowel 
resection due to diverticulosis or polyps were used as controls. Specimens were formalin-fixed and 
paraffin-embedded or frozen in Cryoblock Compound (DiaPath) or frozen on dry ice and stored at 
−80°C. Human studies were approved by the ethics committee of the Istituto Clinico Humanitas.  
Animals and animal handling 
Mice used in this study were male BALB/c-Nude (CAnN.Cg-Foxn1nu/Crl) (Charles River 
Laboratories Italia, Lecco, Italy) 7-11 weeks old. All animals were maintained under pathogen-free 
conditions. Housing was temperature controlled, with a 12 light/12 dark hour cycle. Procedures 
involving mice conformed to institutional guidelines in agreement with national and international law 
and were approved by the ethics committee of the Humanitas Research Hospital.  
Preparation of cell suspensions and transanal mucosal injection 
CT26 mCherry positive cells were harvested from near-confluent cultures by a brief exposure to 0,5% 
trypsin and 0,02% EDTA (Lonza). Cells were washed with PBS 1X-/- and analyzed by FACS for 
mCherry positivity prior to injection. Mice were anesthetized with 100mg/kg ketamine and 50mg/kg 
xylazine. With the use of a 29-gauge syringe, 15000 CT26 mCherry-positive cells were injected 
submucosally into the distal posterior rectum in a final volume of 50µl, as previously described20. 
Tumor growth was visually monitored daily. Mice were sacrificed on post-injection day 19. 
Statistical analyses  
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Statistical analyses were performed using GraphPad Prism 4 (GraphPad Software), with a 2-tailed, 
unpaired Student t test or with the ANOVA test with Bonferroni's or Dunnet’s Multiple Comparison 
Test, as appropriate. Data were presented as means ±SD and differences were considered statistically 
significant when P ≤ 0,05.  
 
Results 
Lymphatic vessel density and the VEGFC/VEGFR3 pathway are altered in human metastatic 
CRC 
Increased lymphatic vessel density in CRC is a key step for metastatic progression5, 21. For this reason 
we first evaluated lymphangiogenesis in colon tissues derived from CRC patients with negative (n=13) 
or positive (n=13) NM stage, and compared them to healthy controls (n=15). We performed an 
immunohistochemical staining for Podoplanin, a widely accepted marker of LVs2. Normal colonic 
biopsies showed sporadic thin LVs in the lamina propria and the submucosa, whereas CRC tissues both 
from non-metastatic (NM-) and metastatic (NM+) patients contained numerous LVs (Figure 1 A). 
Importantly, LVs within NM+ tumoral sections were loaded with metastatic cells (Figure 1 A, black 
arrows). Quantitative analysis revealed that LV density was significantly higher both in NM- and NM+ 
CRC patients, when compared to healthy tissue (Figure 1 B), with no differences between NM- and 
NM+ subjects, thus revealing that lymphangiogenesis occurs in human CRC independently from the 
metastatic process.  
To verify the involvement of VEGFC/VEGFR3 pathway in metastatic CRC-associated 
lymphangiogenesis, human healthy and malignant CRC biopsies were analyzed for the expression of 
these two molecules, by Real-Time PCR, Western blot and immunofluorescence. Figure 1 C showed 
that VEGFC-expression levels were up-regulated in mucosal extracts of CRC patients, when compared 
to control tissues, while the other VEGFR3 ligand, VEGFD didn’t change. This is in accordance with 
other studies, showing reduced levels of VEGFD in metastatic CRC8; for this reason the role of this 
specific growth factor was not taken into consideration for this study.  Notably, VEGFR3-expression 
levels were up-regulated in mucosal extracts from CRC patients, when compared to healthy 
counterparts (Figure 1 D). Moreover, frozen-sections were double-stained for LYVE-1 and VEGFR3 
(Figure 1 E) and their  mean of fluorescence intensity (MFI) quantified, as recently described22. A 
lymphatic specific increase of VEGFR3 (Figure 1 F, left panel) but not LYVE-1 (Figure 1F, right 
panel) in CRC sections was observed compared to control tissues, indicating that the tumor 
microenvironment increases VEGFR3 expression on individual LVs. Collectively, these data 
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demonstrate that lymphatic vascularization is increased in human metastatic CRC, and suggest that the 
tumor microenvironment stimulates the VEGFC/VEGFR3 pathway on LVs, rather than 
VEGFD/VEGFR3 pathway, a finding compatible with tumor-induced lymphangiogenesis.  
The VEGFC/VEGFR3 pathway is actively involved in the metastatic process of a CRC 
orthotopic model 
In several cancer animal models, VEGFC has been found to enhance the passage of metastasis through 
LVs13, 23. To evaluate the functional role of the VEGFC/VEGFR3 pathway in metastatic CRC we 
modulated these two proteins in a well-known CRC mouse model20. Mice that underwent mCherry-
positive CT26 cell orthotopic injection in the rectal mucosa were injected with an adenovirus encoding 
hVEGFC or with an anti-VEGFR3 antibody (mF431C1). Western blot and immunoprecipitation 
analyses of tissue lysates obtained from the colons of each experimental group clearly showed the 
efficient inhibition of VEGFR3 phosphorylation (Supplementary Figure 1 A, left panel) and 
upregulation of hVEGFC (Supplementary Figure 1 A, right panel) at the indicated time points. At 19 
days of treatment lymphnodes (LNs), lungs and livers were processed for metastasis evaluation by 
FACS analysis (Figure 2, A and B). Quantification of mCherry-positive cells showed that systemic 
delivery of VEGFC significantly increased metastasis dissemination to draining LNs, lungs and livers 
(Figure 2 B). On the contrary, mF431C1 completely ablated CT26 migration to LNs, with only few 
cells detected in lungs and liver (Figure 2 B). Notably, the effect observed on metastasis was 
independent from primary tumor growth (Figure 2 C) and was unaltered by the effects of the 
VEGFC/VEGFR3 signaling pathway on CT26 biological functions (Figure 2, D and E). In fact, tumor 
size was unaltered upon VEGFC or mF431C1 treatment (Figure 2 C), and in vitro CT26 cells 
stimulated with VEGFC and/or VEGFR3 inhibitor, did not show any differences in both cell growth 
(Figure 2 D) and invasion (Figure 2 E).  Moreover, CT26 cells did not express VEGFR2, VEGFR3 or 
VEGFC, as revealed by Real-time PCR analysis (Figure 2 F), thus confirming that the CT26-related 
metastatic process was not due to a direct effect of the VEGFC/VEGFR3 pathway on cancer cell 
proliferation and invasion. 
We then evaluated whether the hastened VEGFC/VEGFR3-dependent metastatic dissemination 
correlated with altered lymphangiogenesis. For this purpose colons from CRC-bearing mice treated 
with VEGFC or mF431C1 were evaluated for LV expansion both in terms of LV density and size. 
Untreated tumor bearing mice (CT26) displayed increased LVs density (Figure 3, A and B) and size 
(Figure 3, D and E), when compared to control tumor-free animals (WT). Systemic delivery of the pro-
lymphangiogenic factor VEGFC resulted in increased LV density (Figure 3, A and B) and dimension 
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(Figure 3, D and E), compared to untreated tumor-bearing mice. On the contrary, mF431C1 
administered animals, displayed impaired lymphangiogeneis; in fact only few and small LVs were 
visible compared to untreated tumor bearing mice (Figure 3). Notably, the systemic delivery of  
VEGFC or  VEGFR3 blocking antibody affected only LYVE-1 positive vessels, while these treatments 
did not alter the number (Figure 3 A and C) and dimensions (Figure 3, D and E) of CD31+ blood 
vessels, indicating that the VEGFC/VEGFR3 pathway has no impact on angiogenesis in our CRC 
model. Moreover, to exclude a possible influence of VEGFC and the virus itself on blood endothelial 
cells, Human Intestinal Blood Endothelial Cells (HIBECs) were efficiently infected with the same 
adenoviruses used in vivo (Supplementary Figure 1 B). Results showed that HIBECs proliferation 
(Supplementary figure 1 C), migration (Supplementary figure 1 D) and tubulogenesis (Supplementary 
figure 1 E) were affected neither by the virus itself nor by VEGFC released in the culture medium upon 
infection. Overall, these data demonstrate that VEGFR3 signaling is crucial for CRC progression 
through the lymphatic system, which correlates with the modulation of lymphangiogenesis at the tumor 
site. 
The adherens junction protein VE-Cad is modulated during CRC metastasis on LVs in a 
VEGFC/VEGFR3-dependent manner 
Although many efforts have been made to elucidate the role of VE-Cad expressed on blood vessels 
during cancer progression, little is known about its expression on LVs during tumor invasion, and no 
published data exists regarding its potential link to CRC. We hypothesized that VEGFR3 activation by 
VEGFC could lead to VE-Cad internalization on the lymphatic vasculature. To verify our hypothesis, 
tumor-bearing mice receiving AdVEGFC or mF431C1 treatment were evaluated for VE-Cad 
expression and distribution on colonic LVs. Results revealed that untreated tumor-bearing mice (CT26 
group) had a discontinuous VE-Cad distribution on LVs, compared to control animals (WT group), 
which displayed the canonical button-like and zipper-like junctions24 (Figure 4 A). Interestingly, 
alteration of VE-Cad expression on LVs was even more evident in AdVEGFC treated mice, while upon 
VEGFR3 blocking, was observed a partial restoration of VE-Cad distribution on LVs, compared to 
healthy animals (Figure 4 A). Frozen sections of colons derived from each experimental group, were 
stained for LYVE-1 and VE-Cad (Figure 4 B) and MFI was calculated. Quantification analysis in 
Figure 4 C demonstrated that while untreated tumor-bearing mice displayed a significant reduction in 
VE-Cad MFI compared to healthy controls, systemic delivery of VEGFC significantly decreased VE-
Cad expression, when compared to the CT26 only group. On the contrary, mice treated with mF314C1 
had an increased expression of VE-Cad on LYVE-1-positive vessels, comparable to healthy controls 
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(Figure 4 C). Importantly, similar results were obtained in VEGFC- or mF431C1-treated healthy mice 
(Supplementary Figure 1 F), indicating that the VEGFC/VEGFR3 pathway is actively involved in 
regulating VE-Cad expression and distribution on intestinal LVs both in physiological conditions and 
during metastatic CRC. 
Modulation of VEGFR3 signaling leads to VE-Cad internalization and β-catenin cytoplasmic 
release in HILEC 
To directly study the link between VE-Cad and VEGFR3 signaling in intestinal LVs, we isolated and 
functionally characterized Human Intestinal Lymphatic Endothelial Cells (HILEC)22. For this purpose, 
HILECs were stimulated with VEGFC and/or with SAR131675 (SAR), a tyrosine kinase inhibitor that 
specifically targets VEGFR325. Cells were stained for the lymphatic marker Prox-1 and VE-Cad, and 
cell membrane VE-Cad MFI was quantified. Stimulation with VEGFC increased cytoplasmic VE-Cad 
localization (Figure 5 A, white arrows), when compared to unstimulated cells (UN) and altered VE-Cad 
distribution on HILEC’s cell membrane (Figure 5 A, red arrows), resulting in a discontinuous 
expression pattern of this adherens junction molecule, and a reduced membrane MFI (Figure 5 B). The 
VEGFC-dependent effects were abolished by inhibition of VEGFR3 (Figure 5, A and B). HILECs 
treated only with SAR displayed similar cell membrane VE-Cad localization and MFI, in comparison 
with UN cells, with no internalization of the protein (Figure 5, A and B). These findings show that VE-
Cad distribution and internalization directly depends on VEGFR3 activation by VEGFC, as observed in 
vivo (Figure 4).  
Since in quiescent cells, β-catenin interacts with VE-Cad in complexes mainly at the plasma 
membrane, maintaining a low level of β-catenin at the cytoplasm16, we stained HILECs also for this 
protein (Figure 5 A). VEGFC-treated cells displayed a reduction in β-catenin at the plasma-membrane 
compared to unstimulated HILECs. In the presence of SAR the effects of VEGFC on β-catenin 
membrane localization were lost (Figure 5 A). We therefore measured β-catenin cell membrane MFI. 
Notably, HILECs treated with SAR alone did not display a significant increase in β-catenin, when 
compared with untreated cells. VEGFC-stimulated cells had a lower plasma-membrane β-catenin MFI 
compared to untreated controls, whereas SAR abolished these effects (Figure 5 C). MFI of β-catenin in 
cells treated with the VEGFR3 inhibitor alone was comparable to that of untreated cells. Importantly, 
HIBECs infected with AdVEGFC displayed comparable distribution and internalization of both VE-
Cad and β-catenin (Supplementary Figure 2 A) indicating that VEGFC has a direct effect only on 
LECs. 
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Taken together, these results suggest that VEGFC-dependent VEGFR3 activation impairs cell-cell 
adhesion by inducing the disassembly of the VE-Cad-β-catenin complex at intercellular junctions. 
VEGFR3 activation by VEGFC alters HILEC permeability and affects CT26 cell 
transdentothelial migration 
Cell-cell adherens junctions are important for endothelial barrier function and integrity16. For this 
reason, we assessed the capability of the VEGFC/VEGFR3 signaling pathway to modulate HILECs 
permeability through induction of intercellular junction opening. HILECs were stimulated with 
VEGFC and/or SAR and permeability was assessed by measuring the trans-endothelial electrical 
resistance (TEER). VEGFC-treated HILECs showed a significant decrease in TEER across the cell 
monolayer, when compared to unstimulated cells (Figure 6 A). This effect was abolished by SAR, 
resembling untreated control cells. Notably, SAR-treated HILECs displayed the same TEER as 
untreated cells, demonstrating the specific dependence of intestinal lymphatic endothelial cell 
permeability on VEGFC/VEGFR3 activation. 
To mimic the cancer cell intravasation/extravasation process in vitro, we performed a transendothelial 
migration assay using a co-culture of HILECs and mCherry CT26 cells (Figure 6 B). HILECs were 
treated with VEGFC and/or SAR, and mCherry CT26 transendothelial migration was quantified after 
16 hours of co-culture. Results showed that VEGFC induced an increase in CT26 migration, when 
compared to untreated HILEC. Interestingly, treatment with both VEGFC and the VEGFR3 inhibitor 
showed similar CT26 migration, in comparison to untreated controls (Figure 6, C and D). Moreover, 
HILECs treated with SAR alone displayed a slight reduction in CT26 transmigration (Figure 6, C and 
D), revealing a direct effect of VEGFC-dependent-VEGFR3 activation on CRC cell transendothelial 
migration. Notably, AdVEGFC has no effect on CT26 trasendothelial migration through HIBECs 
(Supplementary Figure 2 B), indicating that VEGFC doesn’t play a role in hematogenous metastatic 
spread. 
LVs in tumor tissue of metastatic CRC patients displayed decreased VE-Cad levels 
To confirm what was observed in vivo and in vitro, we further evaluated VE-Cad expression levels on 
LYVE-1+ vessels in metastatic CRC patients, and compared them with controls. Normal colon tissues 
showed a strong expression of VE-Cad on LVs, whereas CRC sections had a significant cadherin 
decrease (Figure 7 A). Co-expression of VE-Cad and LYVE-1 was quantified revealing a lymphatic 
specific decrease of this cadherin in CRC sections compared with controls (Figure 7 B). This result 
correlated with high levels of both VEGFC and VEGFR3 in the CRC microenvironment. Overall, these 
data demonstrate that lymphatic vascularization is increased in CRC tissues, and that the tumor 
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microenvironment stimulates the VEGFC/VEGFR3 pathway, in association with decreased VE-Cad on 
LVs. These elements contribute to an impaired lymphatic endothelial barrier function and facilitate 
lymphatic metastatic spread, as described in Figure 7 C. Stimulation of VEGFC leads to the induction 
of VEGFR3 signaling causing VE-Cad-β-catenin dissociation, VE-Cad internalization and β-catenin 
cytoplasmic release resulting in cell-junction opening and increased metastatic spread (Figure 7 C). 
 
Discussion  
Tumor induced-angiogenesis and lymphangiogenesis are thought to expedite cancer cell entry into the 
blood and lymphatic vasculature, thus fostering metastatic dissemination14. However, while the role of 
the vascular endothelium in cancer progression is well described26, the contribution of tumoral LVs is 
still unclear. In many types of human cancers, including CRC3-5, the expression of VEGFC2 and its 
receptor, VEGFR325, 27, correlates with lymphangiogenic sprouting, metastases and poor prognosis. In 
accordance with these studies, we confirmed that active lymphangiogenesis takes place in CRC patients 
displaying a high expression of VEGFC and increased VEGFR3 levels on LVs. VEGFD is also known 
to be a VEGFR3 ligand and is considered an important pro-lymphangiogenic factor28; however, unlike 
VEGFC, it was not altered in CRC patients, and for this reason our study only focused on VEGFC. 
Several cancer animal models have highlighted the importance of the lymphatic vasculature in 
metastatic dissemination thanks to the modulation of the VEGFC/VEGFR3 pathway. In fact, He et al. 
demonstrated in a mouse model of lung cancer, that VEGFC-overexpressing LNM35 cells induce 
massive lymphangiogenesis together with lymphatic activation, thus facilitating tumor cell entry in 
LVs and promoting metastatic dissemination to LNs14. Notably, in this study LV destabilization and 
tumor metastases were blocked using an Adenovirus producing a soluble VEGFR3-Ig fusion protein14. 
Moreover, Matsumoto et al. showed that in a mouse model of breast cancer, VEGFR3 signaling was 
required for the early events of the metastatic process and that mF431C1 was able to block both tumor 
lymphangiogenesis and metastases27. In a similar way, our study shows that LVs undergo dramatic 
lymphangiogenic changes in response to nearby CT26 mCherry cells, including sprouting and dilation 
of the larger collecting vessels draining the tumor area. We demonstrate for the first time that upon 
VEGFR3 inhibition, tumor-lymphangiogenesis represents a rate-limiting step for CRC lymphogenous 
metastases, which are significantly suppressed at distant organs. In contrast, upon systemic VEGFC 
delivery, metastasis is fostered in association with active lymphangiogenesis. Consistent with other 
findings, in the tumoral context we do not observe any effects on blood vessel density and enlargement 
upon VEGFC treatment29, 30  or VEGFR3 inhibition7. It is worthy of note that these experiments do not 
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exclude the possibility that VEGFC could act on other cells other than lymphatic endothelial cells, such 
as VEGFR3-expressing macrophages25.  
It is still unclear whether tumor cell intravasation/extravasation requires the transmigration of cancer 
cells through the cytoplasm of endothelial cells, as occurs for leukocytes, or whether they transmigrate 
between two adjacent endothelial cells after the disruption of cell-cell connections19. The endothelial 
barrier integrity is maintained by a complex balance between cell-to-cell adherens junctions. In some 
pathological conditions, such as inflammation and cancer, endothelial junctions can be disrupted 
leading to the opening of intercellular gaps and inducing increased vascular permeability31. We focused 
our attention on the most important player in maintaining barrier integrity: VE-Cad. In fact, blocking 
VE-Cad is sufficient to destabilize endothelial cell contacts in vivo and to increase vascular 
permeability32. In contrast, stabilizing endothelial cell junctions by enhancing the VE-Cad adhesive 
function in knock-in mice leads to the induction of vascular permeability and leukocyte extravasation3, 
33
. One of the mechanisms involved in adherens junction destabilization is the activation of VEGFR2 
by VEGFA which induces VE-Cad tyrosine phosphorylation and its internalization16. In this scenario, 
VEGFA facilitates cancer cell intravasation by disrupting the VE-Cad-β-catenin complex and inducing 
adherens junction weakness and formation of transcellular holes34. Weis et al., provided evidence that 
VEGFA-mediated breakdown in blood endothelial integrity through VE-Cad disruption hastens 
metastases19. Moreover, they demonstrated that VE-Cad inhibition compromises endothelial barrier 
function and promotes tumor cell extravasation19. We hypothesized that similarly to blood vessels, the 
lymphatic vasculature could respond to the modulation of the VEGFC/VEGFR3 pathway with VE-Cad 
redistribution. In vitro results on HILEC confirmed our hypothesis; in fact, VEGFC-induced VEGFR3 
signaling led to VE-Cad-β-catenin complex dissociation, VE-Cad internalization and β-catenin 
cytoplasmic release. Breslin et al. demonstrated that VEGFC-dependent VEGFR3 activation 
significantly increased lymphatic endothelial cell permeability35. In accordance with the above study, 
we provide in vivo evidence that VEGFR3 signaling induces major alterations in the intestinal 
lymphatic barrier and strongly impairs its functionality. Importantly, we propose a mechanism of CRC 
cell intravasation/extravasation that is dependent on VEGFR3 activation on lymphatic endothelial cells 
which facilitates tumor cell entry/exit in a VEGFC-dependent manner. The most intriguing and novel 
finding of our study is that the increased metastasis formation in VEGFC-treated mice during CRC 
progression is not only a consequence of enhanced lymphangiogenesis, but could also be a result of 
VE-Cad distribution and localization on LVs. In fact, VEGFC stimulates LVs sprouting and dilation, 
but also modulates VE-Cad expression on intestinal lymphatics. These results are in accordance with 
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Tammela et al. who observed that VEGFC delivery induces VE-Cad downregulation on lymphatic 
capillaries36. Interestingly, upon VEGFR3 inhibition VE-Cad localization in tumor-bearing mice was 
comparable to healthy animals, thus directly linking VE-Cad distribution with the VEGFC/VEGFR3 
pathway and lymphogenous metastases. These findings confirm our in vitro data and are consistent 
with what we observed in human metastatic CRC specimens. As in the mouse, human CRC samples 
have consistent overexpression of VEGFC and VEGFR3 in tumor tissue which overlaps with increased 
lymphangiogenesis and diminished lymphatic VE-Cad expression. At present, the lymphatic route of 
tumor metastases is less understood compared to the vascular route37. Our results help to better 
understand metastatic dissemination through lymphatics; however, they do not exclude that other 
molecules released in the tumor microenvironment could be involved in lymphatic barrier alteration, 
such as some inflammatory mediators38.   
LVs are largely quiescent in adults39, thus lymphangiogenesis may provide a safe target for cancer 
metastases. The use of neutralizing antibodies targeting VEGFC and/or VEGFR3 in clinical studies 
which have progressed to Phase I clinical trials in patients with advanced solid tumors15 have provided 
encouraging results. Furthermore, several small-molecule protein kinase inhibitors (PKIs) targeting 
various kinases, including VEGFR3, are now available and some of them have been approved for the 
treatment of various cancers15, showing an overall survival benefit in patients with refractory metastatic 
CRC40. 
In summary, our findings strongly support and encourage a VEGFC/VEGFR3-targeted therapy for the 
prevention of CRC metastatic dissemination. The inhibition of this signaling pathway may reduce 
tumor lymphangiogenesis and restore lymphatic barrier integrity through the maintenance of VE-Cad 
distribution on LVs. The lymphatic vasculature may thus represent a potent target to abate and prevent 
CRC lymphogenous spread. 
 
Figure legends: 
Figure 1. Lymphatic vessel density, VEGFC and VEGFR3 signaling are increased in the colon of 
CRC patients 
(A, B) Immunohistochemical staining with an antibody recognizing Podoplanin was performed on 
healthy (NL, n=15), non-metastatic (NM-, n=13) or metastatic (NM+, n=13) CRC colon tissues (A), 
and quantitative analysis of LV density is shown in (B). Data are expressed as mean percentage of LV 
per area ±SD. Bar: 100 µm. **P<0,01, ***P<0,001 by ANOVA test with Bonferroni’s correction for 
multiple comparisons. (C, D) Healthy (NL, n=13) and metastatic CRC (NM+, n=13) patients were 
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measured for VEGFC and VEGFR3 content in mucosal extracts, by Real-time PCR (C) and Western 
blot analysis (D), respectively. (E) Representative images of frozen-sections from the colon of control 
(NL, n=8) or metastatic CRC (NM+, n=8) patients stained for LYVE-1 (red), VEGFR3 (green) and 
DAPI (blue). Bar: 100 µm. (F) The mean fluorescence intensity (FI) per vessel was analyzed on 
VEGFR3+ (left panel) and LYVE-1+ (right panel) LVs (10-15 vessels/patient). FI are relative units 
normalized per vascular area expressed in square micrometers. Values are mean ±SD. *P<0,05, 
**P<0,01 vs. NL by Student’s t-test. M= mucosa, LP= lamina propria, MM=mucolaris mucosae; SM= 
submucosa. 
Figure 2. VEGFC/VEGFR3 pathway activation increases metastatic dissemination of CRC 
without targeting CT26 cells 
Mice receiving mCherry CT26 ortothopic injection were administered with an adenovirus encoding 
hVEGFC, or anti-VEGFR3 antibody (mF431C1). (A, B) FACS analysis shows mCherry-positive cells 
in the liver, lung and LNs. (C) Tumor growth and dimension were measured by IVIS in vivo imaging 
system (left panel) and caliper (right panel). Results are expressed as mean tumor volume (mm3) vs. 
untreated (CT26) of three independent experiments (n= 6 mice/group). (D) CT26 cell proliferation was 
quantified by crystal violet and data are expressed as 560 nm absorbance. Values are mean ± SD of 
three independent experiments with six replicates per group. (E) CT26 cells were subjected to 
migration through matrigel-coated filters for 16 hours and the number of migrated cells vs. UN per 
filter was reported. (F) Confluent CT26 cells were examined for the expression of VEGFR3, VEGFR2 
and VEGFC by Real-time PCR and were compared to healthy mouse colons (Ctrl tissue). Values are 
means ± SD of three independent experiments with three replicates/group. *P<0,05; **P<0,01 vs. 
control (CT26) by ANOVA test with Dunnet’s correction for multiple comparisons.   
Figure 3. The activation of VEGFR3 signaling fosters lymphangiogenesis in CRC 
(A) Representative images of frozen-sections from colons of animals without tumor (WT) and CT26 
bearing mice, with or without adenoviruses encoding hVEGFC, or anti-VEGFR3 antibody (mF431C1). 
Tissues were stained for LYVE-1 (green), CD31 (red) and DAPI (blue), and LYVE-1+ (B) and 
CD31+LYVE1- (C) vessels were counted in 10 comparable regions per section. Results are expressed 
as mean values ± SD, and are representative of three independent experiments (n=3 mice/group). Scale 
bar: 100 µm. (D, E) Whole mounts of distal colonic segments from the indicated experimental groups 
were stained for LYVE-1 (green) and CD31 (red). (D) Representative images of whole mount staining 
of distal colons from the indicated groups. (E) LV and blood vessels diameters were quantified and 
reported as mean values ± SD of three independent experiments, (n=3 mice/group with 5 fields/colonic 
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segment for each experiment). Scale bar 200 µm. ***P<0,001; vs CT26 by ANOVA test with Dunnet’s 
correction for multiple comparisons.  
Figure 4. Systemic delivery of human VEGFC alters VE-Cad pattern distribution and expression 
on LVs 
(A) Representative images of whole mount tissues from colons of animals without tumor (WT) and 
CT26 bearing mice, with or without AdVEGFC, or mF431C1 and stained for LYVE-1 (green) and VE-
Cad (red).  Lower panels are higher magnifications of the white dashed squares in the upper panel. 
Scale bar: 50µm. (B, C) Frozen-sections from the colon of all experimental groups were stained with 
both anti-LYVE-1 and anti-VE-Cad antibodies, with representative images expressed in (B). VE-Cad 
mean FI per vessel was analyzed on LYVE-1+ vessels, and FI is expressed in (C) as relative units per 
vascular area. Scale bar: 20µm. Results are representative of three independent experiments with three 
mice per group. Values are expressed as Mean ±SD. *P<0,05, **P<0,01; vs. CT26 by ANOVA test 
with Dunnet’s correction for multiple comparisons.  
Figure 5. Modulation of the VEGFR3 signaling pathway mediates VE-Cad and β-catenin 
internalization on HILEC 
(A) Representative merges of HILECs stained for the lymphatic marker Prox-1 (magenta), DAPI 
(blue), β-catenin (red) and VE-Cad (green). Cells were left untreated (UN), stimulated for 30 min with 
VEGFC, in the presence or absence of the VEGFR3 inhibitor SAR131675 (SAR). Representative 
merges of HILECs stained for Prox-1 (magenta), DAPI (blue), β-catenin (red) and VE-Cad (green). 
VEGFC stimulation induced VE-Cad internalization (white arrows) along with a discontinuous VE-
Cad membrane distribution (red arrows). (B, C) Cell surface mean FI was analyzed for VE-Cad (B) 
and β-catenin (C). Results are representative of three independent experiments each in triplicate/group. 
Scale bar: 50 µm. Values are expressed as Mean ±SD.  *P<0,05; vs. UN by ANOVA test with 
Dunnet’s correction for multiple comparisons. 
Figure 6. VEGFR3 activation by VEGFC alters HILEC permeability and modulates CT26 cell 
transdentothelial migration 
(A) HILECs permeability was quantified through TEER. Inhibition of VEGFR3 was achieved by 
adding SAR131675 (SAR) (23 µM) 30 min prior to VEGFC (100 ng/ml). Bars represent mean values 
per group ±SD. Bar: 50 µm. *P<0,05; **P<0,01 vs. UN by ANOVA test with Dunnet’s correction for 
multiple comparisons. (B) Cartoon of the transendothelial migration assay: mCherry-CT26 cells were 
seeded on HILEC confluent monolayers left untreated (UN), treated with VEGFC and/or with 
SAR131675, VEGFC+SAR and SAR alone, respectively. MCherry-positive transmigrated cells were 
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counted (D) and representative images are shown in (C). Data are expressed as mean ± SD of 3 
experiments performed in triplicate. Magnification: 10x. ***P<0,001; vs. UN by ANOVA test with 
Dunnet’s correction for multiple comparisons. 
Figure 7. VE-Cad expression is decreased on LVs of metastatic CRC patients 
(A, B) Representative frozen-sections from the colon of control (NL) (n=8) or metastatic CRC (NM+) 
(n=8) patients were stained for both LYVE-1 and VE-Cad (A). Bar: 100µm. (B) VE-Cad mean 
fluorescence intensity (FI) per vessel was analyzed on LYVE-1+ LVs. FI is expressed as relative units 
per vascular area (10-15 vessels/patient). Values are expressed as Mean ± SD. *P<0,05; vs. NL by 
Student’s t-test. (C) The left panel shows that under physiological conditions, intestinal lymphatic 
endothelial cells (ILECs) are quiescent and the barrier integrity is maintained. In the central panel, 
VEGFC secreted in the tumor microenvironment stimulates VEGFR3 overexpressed on ILECs and 
impairs endothelial barrier integrity, thus promoting lymphogenous metastasis formation. In the right 
panel, inhibition of VEGFR3 signaling maintains lymphatic barrier functionality and abates metastasis 
dissemination.  
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Supplemental Material and Methods 
Immunohistochemical staining of Human Colonic Tissues 
To quantify lymphatic vessel (LV) density, the number of Podoplanin-positive LVs was assessed in 
tumor areas of surgical specimens from patients with CRC. Normal areas of the intestine from patients 
admitted for bowel resection due to diverticulitis or polyps were used as controls (NL, n=15). Tissues 
were fixed in 4% buffered formalin, processed, and stained with haematoxylin (DAKO) and eosin 
(Diapath) or immunostained with specific antibodies. Two µm thick sections, of formalin-fixed paraffin 
embedded tissues were deparaffinised in Bioclear (Bioptica) and rehydrated in a descending ethanol 
series. Following antigen retrieval by heating 10 minutes in a microwave with EDTA buffer (pH 8.0; 
0.25 mM), sections were incubated for 20 minutes with Peroxidased-1 solution (Biocare Medical) to 
quench endogenous tissue peroxidase. Tissue slides were then incubated for 60 minutes at room 
temperature in a humid chamber with mouse antihuman Podoplanin monoclonal antibody (clone D2-
40; 1:100; ABD Serotec) and staining was completed using the Biocare Medical HRP-conjugated 
mouse detection kit and diaminobenzidine chromogen as substrate, according to the manufacturer’s 
instructions. Lastly, sections were counterstained with CAT haematoxylin (Biocare Medical) for 5 
minutes. After staining, the slides were dehydrated through graded alcohols and mounted with a cover 
slip using a Eukitt Quick Hardening Mounting Media (Fluka). Negative controls with an omission of 
the primary incubation were also included. The slides were analyzed randomly by two of the authors, 
blinded to clinical data. 
LV density was quantified in the lamina propria and submucosal layers, both areas richly vascularized 
by lymphatic capillaries. Only vessels stained with Podoplanin and visible lumina were considered 
countable, because small nerve fibers and fibroblasts also expressed Podoplanin1 and potentially could 
be confused with collapsed lymphatic capillaries. The mean vessel density of 10 areas with an elevated 
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number of LVs in the 20x magnification objective field, were assessed separately using the VS-ASW 
software (Olympus). 
Real-Time PCR 
RNA was extracted from human tumor and healthy specimen or from healthy mouse colon and CT26 
cell line using the PureZOL RNA isolation reagent (BIORAD) according to manufactured instructions. 
RNA retrotranscription was performed with High Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems®).  Real-Time PCR analyzes were performed starting with cDNA obtained from human 
NM+ tumor (n=13) or healthy (n=13) tissues or from CT26 cell line and mouse colon used as control. 
The primer pairs used are summarized in the table below: 
GENE Product Forward PRIMER Reverse PRIMER 
hVEGFC 5’-CTGCCGATGCATGTCTAAAC-3’ 5’-CTTGTTCGCTGCCTGACAC-3’ 
hVEGFD 5’-CAGTACCTGAATTAGTGCCTG-3’ 5’-ATAGCATGTCAATAGGACAGAG-3’ 
hGAPDH 5’-CATGAGAAGTATGACAACAGC -3’ 5’-AGTCCTTCCACGATACCAAAG-3’ 
mVEGFR3 5’-TATGTCCGAAAGGGCAGTG-3’ 5’-ACACCTTATCAAAGATGCTCTCG-3’ 
mVEGFR2 5’-GACCAAGAGTGACCAAGGGG-3’ 5’-GATTCGGACTTGACTGCCCA-3’ 
mVEGFC 5’-GCGCTGATCCCCAGTCCG-3’ 5’- AGGACAGACATCAGCTCATC-3’ 
mGAPDH 5’-CGTGTTCCTACCCCCAATGT-3’ 5’-TGTCATCATACTTGGCAGGTTTCT-3’ 
 
The reactions were performed on ViiA™7 Real-Time PCR System (Applied Biosystems). GAPDH 
expression was used as housekeeping gene. Data were calculated using the 2^-∆Ct method. 
Cell line culture condition and infection 
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The murine colon cancer CT26 cells were kindly provided by Dr. Giuseppe Celesti (Humanitas 
Clinical and Research Center, Milan, Italy). As demonstrated, the murine colon cancer CT26 cells are 
highly metastatic to liver and lungs2. Cells were maintained in Dulbecco modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum, glutamine, sodium pyruvate, non-essential 
aminoacids and a penicillin-streptomycin amphotericin mixture (Lonza). Adherent monolayer cultures 
were maintained on plastic at 37°C in 5% CO2 and 95% air. All cultures were Mycoplasma free.  
The lentiviral vector pRRLsin.PPT.hPGK.mcherry_pre (kindly provided by Dr. Marco Erreni, 
Humanitas Clinical and Research Center, Milan, Italy) was produced by transient transfection of 293T 
cells according to standard protocols3. Briefly, subconfluent 293T cells were co-transfected with 11,7 
µg of the transfer plasmid, 3,5 µg of the packaging plasmid, 3,5 µg of envelope plasmid and 5 µg of 
rev-expressing plasmid (ViraPowerTM lentiviral packaging mix, Invitrogen) by Lipofectamine 
(Invitrogen). After 16 hours medium was changed, and 24 hours later recombinant lentiviral vectors 
were collected, filtered through 0,22 µm-pore-size cellulose acetate filters and immediately used.  After 
having determined the maximum viral efficiency 105 CT26 cells in six-well plates were used. After 24 
hours CT26 cells were incubated with complete medium and 48 hours later analyzed for infection 
efficiency, by LSRFortessa™ cell analyzer (BD Biosciences). CT26 mCherry cells maintained 
mCherry production for several passages. 
VEGFR3 antibody blockade 
Mice were given intra-peritoneal injections of an anti-mVEGFR3 antibody, mF431C1, (clone 31C1, 
ImClone Systems, 800 µg/100 µl of PBS per mouse)4, 5. Mice were administered intra-peritoneal 
injections three times per week for the entire experiment, starting from the first day after CT26 
mCherry cell injections. A group of mice were sacrificed at 0, 5, 12, and 19 days after CT26 injection 
and mucosal extracts were analyzed by western blot for assessment of VEGFR3 inhibition. All 
experiments were performed in triplicate, using 4-8 mice per experimental group. 
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Adenoviral human VEGFC administration 
Mice were given intra-venous injections of an engineered adenovirus encoding human VEGFC 
(AdVEGFC), or control virus encoding GFP (AdGFP) (not shown) (5x108 PFU/mouse; ViraQuest)5 7 
days before CT26 mCherry cell injections. A group of mice were sacrificed at -7, 5, 12, and 19 days 
from CT26 injection, and mucosal extracts were analyzed by western blot for assessment of human 
VEGFC production. Adenoviral preparation was free from contamination with helper viruses, bacteria 
or lipopolysaccharide. All experiments were performed in triplicate, using 4-8 mice per experimental 
group. 
Tumor dimension 
Before being sacrificed mice were anesthetized with 100mg/kg ketamine and 50mg/kg xylazine and 
fluorescent imaging were performed using a Caliper Xenogen IVIS® Spectrum (Caliper Life Sciences, 
Hopkinton, MA). A light image was obtained for anatomical orientation and fluorescent imaging was 
performed to observe mCherry using standard parameters including 12.9 cm field of view to observe 
three mice simultaneously, excitation filter = 570 nm, emission filter = 620 nm, f-stop 1, pixel binning 
8 and 0.5 seconds exposure time. Images were analyzed using Living Imaging software and the Region 
of Interest (ROI) function. At the indicated time point mice were sacrificed and tumor volume was 
measured by caliper and calculated with the formula V = 0.5×length×width2. 
CT26 proliferation and invasion assay 
A crystal violet assay was used to assess CT26 proliferation, as described previously6. Briefly, CT26 
cells were seeded in 96-well cell culture plates (1×103 cells/well) with complete growth medium 
containing 1% fetal calf serum, and either left untreated or treated with human recombinant VEGFC 
(100 ng/ml; R&D system) or mF431C1 (300 µg/ml, Imclone). Medium was changed every other day 
and after 3 days in culture, cells were stained with 0.2% crystal violet (Sigma) dissolved in ethanol. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Uptake of dye by cells on plates was eluted with 33% acetic acid in water. Plates were gently shaken 
for 20 minutes and the absorbance at 560 nm was measured by a Versamax microplate reader 
(Molecular Devices) at a wavelength of 560 nm. The optical density of each sample was then compared 
with a standard curve, in which the optical density was directly proportional to known cell numbers. 
Invasion assay was assessed by using a BD BioCoat Matrigel invasion chamber with polycarbonate 
filters (8-µm pore size; BD Biosciences), 24 hours serum starved CT26 80x103/filter were plated in the 
upper chamber in DMEM medium, both the upper and the lower chamber were supplemented with 
human VEGFC (100 ng/ml; R&D system) and/or SAR131675 (23 nM dissolved in DMSO; 
Selleckchem). After 16 hours, medium was removed from both chambers, and cells that had migrated 
onto the lower surface of the porous membrane were washed twice in PBS and stained with Diff Quick 
(Medion Diagnostics), according to the manufacturer’s instruction. Triplicates of migrated cells were 
counted in 5 consecutive fields using a 10x objective. All experiments were performed in triplicate. 
Metastasis dissemination assessment 
At the indicated time point mice were sacrificed and liver, lungs, and draining lymphnodes were taken 
for metastasis evaluation by FACS analysis, as previously described7, and a piece of mCherry tumor 
was used as a positive control. Briefly organs were disrupted through a 70 µm filter (BD Falcon) with a 
1 ml syringe plunger and washed with 10 ml of RPMI medium supplemented with 10% fetal calf serum 
and 20 mM Hepes. Liver and lungs were then centrifuged at 800 rpm for 10 minutes to discard debris. 
ACK lysis buffer was used directly on pellets to remove red blood cells. All samples were washed with 
RPMI medium and centrifuged. Samples were then suspended in PBS and counted. 5x106 cells were 
stained with LIVE/DEAD® Dead Cell Stain Kit (Life Technologies) and washed in PBS. Stained cells 
were analyzed using an LSRFortessa™ cell analyzer (BD Biosciences), and data were analyzed using 
the FACSDiva software (BD Biosciences) considering mCherry positive cells on total living cells. All 
experiments were performed in triplicate, using 4 mice per experimental group. 
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Immunofluorescence of human and murine colon tissues 
Frozen sections (6 µm) of human (tumor tissue=8; healthy control=8) and murine colon tissues (n=8 
per experimental group) were fixed in 4% paraformaldehyde solution for 10 minutes and then 
permeabilised in 0.1% Triton X-100 solution for 20 minutes at room temperature. Tissue sections were 
then blocked with PBS containing 2% bovine serum albumin, 0.05% Tween and 2% goat (for human 
colon tissues) or donkey serum (for murine colon tissue) for 30 minutes at room temperature. After 
blocking, human colon sections were incubated with mouse anti-VEGFR3 (1:100; Millipore) or mouse 
anti-VE-Cad (1:50; abcam), and rabbit anti-LYVE-1 (1:200; abcam) antibodies for 2 hours. Murine 
colon sections were incubated overnight at 4°C with rabbit anti-CD31 (1:100; Life Science 
Biotechnology) and/or anti-VE-Cad (1:100; eBioscience) and goat anti-LYVE-1 (1:50; R&D systems) 
primary antibodies. All sections were subsequently incubated for 30 minutes with anti-mouse Alexa 
Fluor 647-conjugated, anti-rabbit Alexa Fluor 488-conjugated, anti-goat Alexa Fluor 488-conjugated, 
anti-rat Alexa Fluor 488-conjugated, and anti-rabbit Alexa Fluor 594-conjugated antibodies (1:1000; 
Molecular Probes), followed by incubation with DAPI for nuclear staining (1:25000; Invitrogen). 
Sections were mounted with ProLong Gold mounting medium (Invitrogen) and analyzed with a laser 
scanning confocal microscope (FluoView FV1000; Olympus).  
Whole mount staining 
Colons were removed from untreated (UN) and treated mice subjected to orthotopic CRC protocol with 
the indicated treatments (n=5-8 mice each experimental group), and immersed in 1% paraformaldehyde 
fixative solution, overnight at 4°C. Tissues were then washed and incubated with anti-CD31 (1:500; 
Millipore), rabbit anti-LYVE-1 (1:500; abcam) and rat anti-VE-Cad (1:200; eBioscience) antibodies 
diluted in PBS containing 0.3% Triton X-100, 2% bovine serum albumin, 5% goat serum, 0.01% 
glycine, and 0.1% sodium azide, overnight at 4°C. Anti-hamster Alexa Fluor 647, anti-rabbit Alexa 
Fluor 594 (1:500; Molecular Probes) and anti-rat Alexa Fluor 488 (1:500; Molecular Probes) were used 
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as secondary antibodies, and incubated overnight at 4°C. Samples were then mounted with Vectashield 
(Vector Laboratories) and imaged with a laser scanning confocal microscope (Fluoview FV1000; 
Olympus). 
Morphometric and immunofluorescence intensity measurements  
Morphometric analysis of colon whole mounts was performed by 3D visualization of LVs. Images 
were taken as a z series stack using a 10x objective, and analyzed by Imaris Bitplane software, thus 
allowing visualization of the LVs in the submucosal and serosal-muscular layers. For each colon 
analyzed (n=5-8 mice each experimental group), LV density and size were measured in 10 randomly 
chosen regions covered by vessels (each 1.0 mm2 in area) and were represented as average number of 
vessels per area (mm2) and mean value of diameters (µm), respectively. 
The number of LYVE-1-, VEGFR3-, or VE-Cad-positive vessels in single and double-stained murine 
colon tissues was established by stereological point counting of 10 regions per section (mucosal, 
submucosal and serosal layers), each 1.5 mm2 in area, using the FluoView software (Olympus). We 
considered as LVs only LYVE-1 positive vessel with a visible lumen. Values are expressed as mean 
number of positive vessels per square millimeter. Analysis of human and mouse VEGFR3 and/or VE-
Cad and LYVE-1 double-staining, was performed as described by Tammela et al.8, with slight 
modifications. In brief, murine colon sections (n=8 mice each experimental group) were double-stained 
with rabbit anti-LYVE-1 (1:400; abcam) and rat anti-VE-Cad (1:100; eBioscience) primary antibodies, 
while staining of human colon sections are described above. Fluorescent images were acquired at a 
constant exposure time at 20x or 60x magnification on a laser scanning confocal microscope 
(FluoView FV1000; Olympus). Colons stained with secondary antibodies alone were used to set the 
exposure time. Vascular structures with a lumen were analyzed with FluoView software (Olympus) and 
all images were within a linear intensity range between 0 and 6231. To exclude nonspecific staining, 
structures less than 8 µm (1 µm = 6.8 pixels) in diameter were excluded. To calculate mean vessel 
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intensity, the sums of pixel intensities per vessel were divided by total vessel area (µm2). Mean vessel 
fluorescence intensity (FI) from 5 to 10 images per specimen were averaged and compared between 
treated and control groups (mouse) and healthy and tumor (human). 
Isolation and culture of HILEC and HIBEC 
HILEC were obtained from human intestinal microvascular endothelial cells (HIMEC), which were 
isolated as previously described5, 9. Briefly, HIMEC were obtained from normal areas of the intestine of 
patients admitted for bowel resection of colon cancer, polyps, or diverticulitis (n=10). HIMEC were 
isolated by enzymatic digestion of intestinal mucosal strips followed by gentle compression to extrude 
endothelial cell clumps, which adhere to fibronectin-coated plates and were subsequently cultured in 
MCDB131 medium (Sigma) supplemented with 20 % fetal calf serum, antibiotics, heparin, and 
endothelial cell growth factor. After 9 days in culture, as previously reported5, cells were trypsinised 
and incubated with the following antibodies: anti-human Podoplanin (1 mg per 106 cells; Santa Cruz), 
anti-human VEGFR3 (625 ng per 105 cells; R&D system), and PE-conjugated mouse anti-human CD31 
antibody (10 µl per 106 cells) followed by incubation with Alexa Fluor 647- and Alexa Fluor 488-
conjugated secondary antibodies (Molecular Probes). HILEC were then sorted on a FACSAria IIU (BD 
Biosciences), using a FACSDiva software (version 6.1.3; BD Biosciences), by positive selection for 
Podoplanin and VEGFR3 gated on a CD31-positive cell population cells (BD Pharmingen) and HIBEC 
by gating on CD31-positive and Podoplanin and VEGFR3 negative cell population. Cultures of HILEC 
and HIBEC were maintained at 37°C in 5% CO2, fed twice a week, and split at confluence. HILEC and 
HIBEC were used between passages 2 and 6. 
HIBEC adenoviral infection 
HIBEC were seeded on 6 well plates and infected with AdVEGFC or AdGFP (MOI=500), used as a 
control, or left untreated in MCDB131 complete medium supplemented with 2% fetal calf serum. After 
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6 hours medium wash replaced with fresh MCDB131 complete medium supplemented with 20% fetal 
calf serum and used after 2 days. 
Immunoprecipitation and Western Blotting  
Human colonic samples from CRC-involved area (n=13) and healthy controls (n=13) or mouse colon 
tissues from animals with the indicated treatments and at the indicated time points (n=3/group/time) 
were mechanically homogenized in lysis buffer for protein extraction. Infected HIBECs and controls 
were scraped in lysis buffer for protein extraction while medium was collected for VEGFC evaluation. 
Insoluble material was removed by centrifugation for 30 minutes at 14,000 rpm at 4°C and the 
concentration of proteins in each lysate was measured using the Bio-Rad protein assay (Bio-Rad 
Laboratories). For immunoprecipitation, mouse extracts were pre-cleared with lysis buffer-containing 
protein-G agarose beads for 1 hour at 4°C. Pre-cleared lysates (1 mg) were incubated with an antibody 
against mouse VEGFR3 (1 µg/ml in lysis buffer; R&D system) overnight at 4°C. After washing with 
lysis buffer, the immunoprecipitates were resuspended in 50 µl of SDS-sample buffer, incubated at 
95°C for 5 minutes and immunoblotted, as described below.  
Proteins (80 µg for tissue homogenate and 50 µg for cell lysates), cell culture medium (50 µl) and 
immunoprecipitates were separated on a 10% Tris-glycine gel and electrotransferred to a nitrocellulose 
membrane (Bio-Rad Laboratories). Nonspecific binding was blocked with Tris-buffered saline (TBS) 
containing 5% non-fat dried milk and 0.1% Tween 20, followed by overnight incubation at 4°C with 
the rabbit anti-human VEGFR3 antibody (1:500; Life Technologies), the rabbit anti-human VEGFC 
antibody (1:1000; abcam), and an anti–actin antibody (1:1000; Santa Cruz Biotechnology) as loading 
control. Mouse anti-phosphotyrosine (1:1000; Millipore) and anti-mouse VEGFR3 (1:500; ImClone 
Systems) antibodies were used to visualize immunoprecipitated samples. Membranes were washed for 
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1 hour with TBS containing 0.1% Tween 20 and then incubated for 1 hour with the appropriate 
horseradish peroxidase-conjugated secondary antibody (1:3000; GE Healthcare). The membranes were 
then incubated with Immobilon Western Chemilum (Millipore) for 1 minute, after which bands were 
detected by Chemidoc (Bio-Rad Laboratories), using Quantity One software. 
Tubule formation assay, migration assay and proliferation assay 
HIBEC tube formation was assessed using Matrigel (BD Biosciences) as previously describe5. Briefly, 
multiwell dishes were coated with 250 µL of complete medium containing 5 mg/ml Matrigel for 30 
minutes at 37°C HIBEC were seeded in triplicate at a density of 5×104 in complete MCDB131 medium 
infected with AdVEGFC, AdGFP or untreated. Cells were cultured on Matrigel for 4 hours, and 
inverted phase-contrast microscopy was used to assess and count endothelial tube-like structures. Five 
high-power fields per condition were examined. All experiments were repeated three times. 
Migration assay was assessed as previously reported9, with some modifications. By using a BD 
BioCoat Matrigel invasion chamber with polycarbonate filters (8µm pore size; BD Biosciences), 
starved (MCDB131 for 18 hours) HIBEC (50 x 103/filter) were plated in the upper chamber in 
MCDB131 medium. After 18 hours, medium was removed from both chambers, and cells that had 
migrated onto the lower surface of the porous membrane were washed twice in PBS and stained with 
Diff Quick (Medion Diagnostics), according to the manufacturer’s instruction. Triplicates of migrated 
cells were counted in the entire membrane using a 20x objective. Proliferation for HIBEC was 
evaluated as described above for CT26 cells with brief modifications. Briefly, HIBEC were seeded in 
96-well cell culture plates (1×103 cells/well) with MCDB131 medium. HIBEC were previously 
infected with AdVEGFC, AdGFP or not infected. Medium was changed every other day and after 4 
days in culture, cells were stained with 0.2% crystal violet (Sigma) dissolved in ethanol. Uptake of dye 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
by cells on plates was eluted with 33% acetic acid in water. Plates were gently shaken for 20 minutes 
and the absorbance at 560 nm was measured by a Versamax microplate reader (Molecular Devices) at a 
wavelength of 560 nm. The optical density of each sample was then compared with a standard curve, in 
which the optical density was directly proportional to known cell numbers. 
HILECs immunofluorescence and evaluation of VE-Cad internalization 
Serum starved (MCDB131 for 24 hours) confluent HILEC were left unstimulated or stimulated with 
VEGFC (100 ng/ml; R&D system) and/or SAR131675 (23 nM dissolved in DMSO; Selleckchem) for 
30 minutes in starving medium. HIBEC infected for AdVEGFC, AdGFP or not infected were serum 
starved for 1 hour. Cells were fixed with 4% paraformaldehyde fixative solution for 10 minutes at room 
temperature, washed with PBS and blocked and permeabilized with 5% fetal calf serum, 5% human 
serum, 2% bovine serum albumin, 0.1% Triton X-100 solution for 30 minutes at room temperature. 
After blocking, HIBEC were incubated with mouse anti-VE-Cad (1:100; BD Bioscience), rabbit anti-β-
catenin (1:600; abcam), and HILECs also with goat anti-Prox1 (1:80; R&D systems) antibodies 
overnight at 4°C. After washing HILECs were subsequently incubated for 1 hour with anti-goat Alexa 
Fluor 647-conjugated, anti-rabbit Alexa Fluor 594-conjugated and anti-mouse Alexa Fluor 488-
conjugated antibodies (1:1000; Molecular Probes), and HIBEC with anti-rabbit Alexa Fluor 594-
conjugated and anti-mouse Alexa Fluor 647-conjugated antibodies followed by incubation with DAPI 
for nuclear staining (1:25000; Invitrogen) for 10 minutes at room temperature. Cover glasses were 
mounted with ProLong Gold mounting medium (Invitrogen) and. Fluorescent images were acquired at 
a constant exposure time at 60x magnification on a laser scanning confocal microscope (FluoView 
FV1000; Olympus). To calculate mean membrane intensity, the sums of pixel intensities per cell 
membrane were subtracted from inner membrane pixel intensities. Mean membrane fluorescence 
intensity (FI) from 10 images per treatment were averaged and compared between treated and control 
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groups. VE-Cad internalization experiments were performed in triplicates and are the result of 3 
independent experiments. 
HILEC permeability assay 
HILECs were seeded on fibronectin coated 0.4 µm pore-size Transwell Permeable Supports (Corning 
Costar, Cambridge, MA), cultured in complete culture medium and let to form a monolayer, as 
previously described10. After the establishment of a stable monolayer HILECs were serum starved for 
24 hours and then were stimulated with VEGFC (100 ng/ml; R&D system) and/or with SAR131675 
(23 nM dissolved in DMSO; Selleckchem) and assayed for permeability using a Millicall-ERS 
voltohmmeter (World Precision Instruments, New Haven, CT) to measure the transendothelial 
electrical resistance (TEER) as previously described. The percentage of change in the TEER was 
calculated with respect to time 0 for each indicated time point. Experiments were performed in 
triplicates and are the result of 3 independent experiments. 
Transendothelial migration assay 
BioCoat Matrigel invasion chamber with polycarbonate filters (8-µm pore size; BD Biosciences) were 
seeded with HILECs or HIBECs in complete medium. After the establishment of a stable monolayer 
HILECs were stimulated with VEGFC (100 ng/ml; R&D system) and/or with SAR131675 (23 nM 
dissolved in DMSO; Selleckchem) for 24 hours. HIBECs infected with AdVEGFC or GFP or untreated 
were cultured in complete medium to establish a stable monolayer. MCherry CT26 cells were 
trypsinised, counted and plated on top of HILEC monolayer in the presence of VEGFC (100 ng/ml; 
R&D system) and/or SAR131675 (23 nM dissolved in DMSO; Selleckchem) or on HIBECs in 
complete medium. After 16 hours mCherry CT26 transmigrated cells were counted in 5 consecutive 
fields with a 10x zoom fluorescent microscope. Experiments were performed in triplicates and are the 
result of 3 independent experiments. 
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Supplemental Figure Legend: 
 
Supplementary Figure 1 
Mice receiving mCherry CT26 ortothopic injection were administered with an adenovirus encoding 
hVEGFC (n=3/time point), or anti-VEGFR3 antibody (mF431C1, n=3/time point). (A) Colonic 
samples from healthy and tumor-bearing mice with the indicated treatments and at the indicated time 
points were mechanically homogenized in lysis buffer for protein extraction. Representative blots for 
immunoprecipitation and immunoblotting are shown. Days are relative to CT26 injections. (B-E)  
HIBEC were infected with AdVEGFC, AdGFP or not infected. (B) Western blot performed on cell 
lysates or medium demonstrated that VEGFC was produced at low levels by HIBEC and it was 
efficiently secreted when cells were infected with AdVEGFC. HIBEC infected with AdVEGFC, 
AdGFP or left untreated (UN) displayed comparable proliferation (C), migration (D) and capillary 
formation (E). Results are representative of three independent experiments each in triplicate/group. 
Values are expressed as Mean ±SD. (F) Representative images of colonic whole mount staining of 
mice without tumor (WT) and groups administered with adenoviruses encoding hVEGFC, or anti-
VEGFR3 antibody (mF431C1) stained for LYVE-1 (green) and VE-Cad (red).  WT group (left upper 
panel), is visible the canonical “button and zippers” VE-Cad distribution; AdVEGFC-injected group, 
revealed a discontinuous VE-Cad LVs’ distribution; VEGFR3 inhibition with mF431C1 increased VE-
Cad on LVs. Lower panels are higher magnifications of the white dashed squares in the upper panel. 
Scale bar: 50µm. 
 
Supplementary Figure 2 
(A) Representative merges of HIBECs stained for DAPI (blue), β-catenin (red) and VE-Cad (white) or 
expressing GFP (green). Cells were not infected (UN) or infected with AdVEGFC or AdGFP displayed 
similar VE-Cad and β-catenin distribution. Scale bar: 50µm. Transendothelial migration assay: 
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mCherry-CT26 cells were seeded on HIBEC confluent monolayers not infected, infected with 
AdVEGFC or with AdGFP. MCherry-positive transmigrated cells were counted (B). Results are 
representative of three independent experiments each in triplicate/group and values are expressed as 
Mean ±SD. 
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